Needham raised the firm’s price target on Collegium Pharmaceutical to $36 from $35 and keeps a Buy rating on the shares. The company announced that FDA granted a New Patient Population exclusivity for Nucynta IR, which effectively extends the U.S. exclusivity period of the product from June 2025 to July 2026, and the firm adjusts its model to reflect the additional exclusivity that will allow Collegium to harvest Nucynta revenues – currently $180M-$190M in annual sales – for an additional year, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on COLL:
- Collegium extends of Nuncynta regulatory exclusivity through July 2026
- Collegium Announces $50 Million Accelerated Share Repurchase Program
- Collegium Pharmaceutical announces $50M accelerated share repurchase program
- Collegium Pharmaceutical reports Q2 EPS 34c, consensus 29c
- Collegium Reports Record 1H’23 Net Revenue of $280.3 Million, Up 35% Year-over-Year
